Register a trial

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01750190




Registration number
NCT01750190
Ethics application status
Date submitted
11/12/2012
Date registered
17/12/2012

Titles & IDs
Public title
A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis
Scientific title
A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Roxadustat (FG-4592) for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis
Secondary ID [1] 0 0
FGCL-4592-060
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
CKD Anemia 0 0
Condition category
Condition code
Renal and Urogenital 0 0 0 0
Kidney disease
Renal and Urogenital 0 0 0 0
Other renal and urogenital disorders
Blood 0 0 0 0
Anaemia

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Roxadustat
Treatment: Drugs - Placebo

Experimental: Roxadustat - Participants will receive roxadustat tablets orally 3 times a week (TIW). The initial dose will be according to the tiered weight-based approach, with starting roxadustat doses of 70 milligrams (mg) TIW to participants weighing \<70 kilograms (kg) and roxadustat doses of 100 mg TIW to participants weighing =70 kg. Dose-titration (up to a maximum dose of 300 mg) will be performed based upon regular measurement of Hb levels until the participant achieves central Hb value of =11.0 grams/deciliter (g/dL) and Hb increase from baseline (BL) of =1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level is reached, the participant will enter the maintenance period during which roxadustat dosage will be adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration will be up to 234.9 weeks.

Placebo comparator: Placebo - Participants will receive roxadustat-matching placebo tablets orally TIW. The initial dose will be according to the tiered weight-based approach, with starting roxadustat-matching placebo doses of 70 mg TIW to participants weighing \<70 kg and roxadustat-matching placebo doses of 100 mg TIW to participants weighing =70 kg. Dose-titration (up to a maximum dose of 300 mg) will be performed based upon regular measurement of Hb levels until the participant achieves central Hb value of =11.0 g/dL and Hb increase from BL of =1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level is reached, the participant will enter the maintenance period during which roxadustat dosage will be adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration will be up to 208.1 weeks.


Treatment: Drugs: Roxadustat
Oral tablets

Treatment: Drugs: Placebo
Oral tablets
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
United States (US FDA) Submission: Mean Change From Baseline in Hb (g/dL) Over Weeks 28 to 52 Regardless of Rescue Therapy
Timepoint [1] 0 0
Baseline (Day 1, Week 0), Weeks 28 to 52
Primary outcome [2] 0 0
Ex-US Submission: Number (%) of Participants Who Achieved a Hb Response During the First 24-Weeks of Treatment Censoring for Rescue Therapy
Timepoint [2] 0 0
Baseline up to Week 24
Secondary outcome [1] 0 0
Mean Change From Baseline in Hb Averaged Over Weeks 28 to 36 With Censoring for Rescue Therapy
Timepoint [1] 0 0
Baseline (Day 1, Week 0), Weeks 28 to 36
Secondary outcome [2] 0 0
Mean Change From Baseline in Hb Averaged Over Weeks 28 to 52 Regardless of Rescue Therapy in Participants With Baseline C-Reactive Protein (CRP) >Upper Limit of Normal (ULN)
Timepoint [2] 0 0
Baseline (Day 1, Week 0), Weeks 28 to 52
Secondary outcome [3] 0 0
Number (%) of Participants With Hb =10 g/dL Averaged Over Weeks 28 to 36 With Censoring for Rescue Therapy
Timepoint [3] 0 0
Weeks 28 to 36
Secondary outcome [4] 0 0
Mean Change From Baseline in Low-Density Lipoprotein (LDL) Cholesterol Averaged Over Weeks 12 to 28
Timepoint [4] 0 0
Baseline (Day 1, Week 0), Weeks 12 to 28
Secondary outcome [5] 0 0
Rate of Change in eGFR From Baseline up to 12 Months (Linear Random Coefficient Model With Observed Data)
Timepoint [5] 0 0
Baseline, Month 12
Secondary outcome [6] 0 0
Number of Participants Who Received Blood/RBC Transfusion in the First 52 Weeks of Treatment
Timepoint [6] 0 0
Baseline up to Week 52
Secondary outcome [7] 0 0
Number (%) of Participants Who Received Rescue Therapy in the First 24 Weeks and in the First 52 Weeks of Treatment
Timepoint [7] 0 0
Baseline (Day 1, Week 0) up to Week 24 and up to Week 52
Secondary outcome [8] 0 0
Change From Baseline in Short Form 36 (SF-36) Version 2 Physical Functioning Subscore and Vitality Subscore at Weeks 12 to 28
Timepoint [8] 0 0
Baseline (Day 1, Week 0), Weeks 12 to 28
Secondary outcome [9] 0 0
Number (%) of Participants Who Experienced Exacerbation of Hypertension
Timepoint [9] 0 0
Baseline up to Week 52
Secondary outcome [10] 0 0
Mean Change From Baseline in Mean Arterial Pressure (MAP) Averaged Over Weeks 20 to 28
Timepoint [10] 0 0
Baseline, Weeks 20 to 28

Eligibility
Key inclusion criteria
* Chronic kidney disease Stages 3, 4, or 5 and not receiving dialysis
* Anemia qualified by measurements of hemoglobin values during screening
* Additional blood work must be in a safe range for study entry
* Body weight 45 to 160 kilograms (kg)
* Willingness to use contraception if of child-bearing potential
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Treatment with an erythropoiesis-stimulating agent (ESA) within 12 weeks prior to study participation
* More than 1 dose of intravenous iron within 12 weeks prior to study participation
* Blood transfusion within 8 weeks prior to study participation
* Active infection
* Chronic liver disease
* Severe congestive heart failure, recent heart attack, stroke, seizure, or blood clot
* Uncontrolled blood pressure within 2 weeks prior to study participation
* Renal cell carcinoma
* History of malignancy, including multiple myeloma or other myelodysplastic syndrome
* Chronic inflammatory disease that could impact red blood cell production
* Any prior organ transplant or a scheduled organ transplantation
* Anticipated elective surgery that is expected to lead to significant blood loss or anticipated elective heart procedure
* Gastrointestinal bleeding
* Any prior treatment with roxadustat or a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI)
* Recent use of an investigational drug or treatment, or participation in an investigational study

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
5/11/2012
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
24/09/2018
Sample size
Target
Accrual to date
Final
922
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Investigational Site - Liverpool
Recruitment hospital [2] 0 0
Investigational Site - Gosford
Recruitment hospital [3] 0 0
Investigational Site - Hobart
Recruitment hospital [4] 0 0
Investigational Site - Launceston
Recruitment hospital [5] 0 0
Investigational Site - Melbourne
Recruitment hospital [6] 0 0
Investigational Site - New Lambton Heights
Recruitment hospital [7] 0 0
Investigational Site - Randwick
Recruitment postcode(s) [1] 0 0
2170 - Liverpool
Recruitment postcode(s) [2] 0 0
2250 - Gosford
Recruitment postcode(s) [3] 0 0
7000 - Hobart
Recruitment postcode(s) [4] 0 0
7250 - Launceston
Recruitment postcode(s) [5] 0 0
3004 - Melbourne
Recruitment postcode(s) [6] 0 0
2305 - New Lambton Heights
Recruitment postcode(s) [7] 0 0
2031 - Randwick
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Idaho
Country [7] 0 0
United States of America
State/province [7] 0 0
Louisiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Maryland
Country [9] 0 0
United States of America
State/province [9] 0 0
Massachusetts
Country [10] 0 0
United States of America
State/province [10] 0 0
Michigan
Country [11] 0 0
United States of America
State/province [11] 0 0
Missouri
Country [12] 0 0
United States of America
State/province [12] 0 0
New Jersey
Country [13] 0 0
United States of America
State/province [13] 0 0
New Mexico
Country [14] 0 0
United States of America
State/province [14] 0 0
New York
Country [15] 0 0
United States of America
State/province [15] 0 0
North Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Pennsylvania
Country [17] 0 0
United States of America
State/province [17] 0 0
South Carolina
Country [18] 0 0
United States of America
State/province [18] 0 0
Tennessee
Country [19] 0 0
United States of America
State/province [19] 0 0
Texas
Country [20] 0 0
United States of America
State/province [20] 0 0
Virginia
Country [21] 0 0
United States of America
State/province [21] 0 0
West Virginia
Country [22] 0 0
Argentina
State/province [22] 0 0
Buenos Aires
Country [23] 0 0
Argentina
State/province [23] 0 0
Provincia De Buenos Aires
Country [24] 0 0
Argentina
State/province [24] 0 0
Provincia De Cordoba
Country [25] 0 0
Argentina
State/province [25] 0 0
Cordoba
Country [26] 0 0
Argentina
State/province [26] 0 0
Corrientes
Country [27] 0 0
Argentina
State/province [27] 0 0
Mendoza
Country [28] 0 0
Argentina
State/province [28] 0 0
Salta
Country [29] 0 0
Argentina
State/province [29] 0 0
Santa Fe
Country [30] 0 0
Chile
State/province [30] 0 0
Region De La Araucania
Country [31] 0 0
Chile
State/province [31] 0 0
Region Metropolitana
Country [32] 0 0
Colombia
State/province [32] 0 0
Atlantico
Country [33] 0 0
Colombia
State/province [33] 0 0
Cundinamarca
Country [34] 0 0
Hong Kong
State/province [34] 0 0
Pokfulam
Country [35] 0 0
Hong Kong
State/province [35] 0 0
Chai Wan
Country [36] 0 0
Hong Kong
State/province [36] 0 0
Shatin
Country [37] 0 0
Hong Kong
State/province [37] 0 0
Tai Po
Country [38] 0 0
Korea, Republic of
State/province [38] 0 0
Gyeonggi-Do
Country [39] 0 0
Korea, Republic of
State/province [39] 0 0
Busan
Country [40] 0 0
Korea, Republic of
State/province [40] 0 0
Seoul
Country [41] 0 0
Malaysia
State/province [41] 0 0
Alor Setar
Country [42] 0 0
Malaysia
State/province [42] 0 0
Kajang
Country [43] 0 0
Malaysia
State/province [43] 0 0
Kuala Lumpur
Country [44] 0 0
Malaysia
State/province [44] 0 0
Kuching
Country [45] 0 0
Malaysia
State/province [45] 0 0
Pulau Pinang
Country [46] 0 0
Malaysia
State/province [46] 0 0
Sungai Petani
Country [47] 0 0
Malaysia
State/province [47] 0 0
Taiping
Country [48] 0 0
Mexico
State/province [48] 0 0
Distrito Federal
Country [49] 0 0
Mexico
State/province [49] 0 0
Jalisco
Country [50] 0 0
Mexico
State/province [50] 0 0
Nuevo Leon
Country [51] 0 0
Mexico
State/province [51] 0 0
Yucatan
Country [52] 0 0
Mexico
State/province [52] 0 0
Aguascalientes
Country [53] 0 0
Mexico
State/province [53] 0 0
San Luis Potosi
Country [54] 0 0
New Zealand
State/province [54] 0 0
Auckland
Country [55] 0 0
New Zealand
State/province [55] 0 0
Hamilton
Country [56] 0 0
New Zealand
State/province [56] 0 0
Tauranga
Country [57] 0 0
Peru
State/province [57] 0 0
Callao
Country [58] 0 0
Peru
State/province [58] 0 0
Lima
Country [59] 0 0
Philippines
State/province [59] 0 0
Cavite
Country [60] 0 0
Philippines
State/province [60] 0 0
Davao
Country [61] 0 0
Philippines
State/province [61] 0 0
Pasig
Country [62] 0 0
Philippines
State/province [62] 0 0
Quezon City
Country [63] 0 0
Puerto Rico
State/province [63] 0 0
Ponce
Country [64] 0 0
Puerto Rico
State/province [64] 0 0
San Juan
Country [65] 0 0
Singapore
State/province [65] 0 0
Singapore
Country [66] 0 0
Taiwan
State/province [66] 0 0
Changhua
Country [67] 0 0
Taiwan
State/province [67] 0 0
Hualien City
Country [68] 0 0
Taiwan
State/province [68] 0 0
Kaohsiung
Country [69] 0 0
Taiwan
State/province [69] 0 0
Taichung
Country [70] 0 0
Taiwan
State/province [70] 0 0
Tainan City
Country [71] 0 0
Taiwan
State/province [71] 0 0
Tainan
Country [72] 0 0
Taiwan
State/province [72] 0 0
Taipei
Country [73] 0 0
Thailand
State/province [73] 0 0
Bangkok
Country [74] 0 0
Thailand
State/province [74] 0 0
Chiang Mai

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
FibroGen
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Astellas Pharma Europe B.V.
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Commercial sector/industry
Name [2] 0 0
AstraZeneca
Address [2] 0 0
Country [2] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Mark Eisner, MD, MPH
Address 0 0
FibroGen
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
When will data be available (start and end dates)?
Available to whom?
Available for what types of analyses?
How or where can data be obtained?


What supporting documents are/will be available?




Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results are available at https://clinicaltrials.gov/study/NCT01750190